OS Therapies announced that the World Health Organization has approved 'Herlystic' as the brand name for its gene-edited cancer immunotherapy OST-HER2. With both the proprietary and nonproprietary names approved, the company is set to begin regulatory submissions for early market access, starting with the UK's MHRA under Project Orbis, followed by submissions to the FDA, EMA, and TGA. OST-HER2 targets metastatic osteosarcoma and has received multiple designations including Orphan Drug and Fast Track from various regulatory bodies. The company plans to leverage clinical data and regulatory programs to expedite approval and potentially obtain a Priority Review Voucher in the US.
OS Therapies' gene-edited cancer immunotherapy OST-HER2 is highlighted here with Pluang's health sector market context as of Sep 24, 2026 18:22 WIB: Among 100 priced US health stocks, 37 rose and 59 fell. Notable movers include InMode Ltd (INMD) at USD 13.93 with a 1-day change of -1.83% and a typical hold time of 28 days, Biogen Inc (BIIB) at USD 223.67 down 1.70% with a typical hold time of 111 days, and Cronos Group Inc (CRON) at USD 3.45 up 1.47% with a typical hold time of 22 days. Pluang order activity for INMD was 100% sell.
Gold and silver prices fell modestly as rising oil prices, strong US economic data, and expectations of further Fed rate hikes outweighed safe-haven demand from US-Iran tensions. Spot gold dropped 0.48% to around $4,265 an ounce, while silver fell 1....
A federal disclosure reveals that President Trump purchased shares of SpaceX shortly after its 2026 IPO and sold some a week later. The trades were small relative to SpaceX's massive market value, but the president's ownership raises concerns about p...
Apple is showing a slight pullback after forming a potential double top pattern near its recent high, with value buyers likely to step in if prices dip. Microsoft remains range-bound below a key resistance at $518, with a breakout needed to resume it...
The 10-year US Treasury yield has reached a resistance level at 5%, its highest since 2007, signaling a potential ceiling for further increases. This yield pressure affects borrowing costs and various financial sectors, including mortgages and corpor...
Aehr Test Systems projects significant revenue growth of 160% to 200% year-over-year for fiscal year 2027, driven by strong demand for AI and data center testing equipment and a large backlog of orders. Management forecasts revenue between $130 milli...
